Mobile

A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib at 6 mg/kg/day versus placebo in pat...

Update Il y a 4 ans
Reference: EUCTR2010-021495-29

A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib at 6 mg/kg/day versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with severe COPD. Primary endpoint: • Absolute change from randomisation in the 6-minutes walking distance test at Week 24

Inclusion criteria

  • Severe Chronic Obstructive Pulmonary Disease (COPD)

Links